Product Description
Bepotastine ophthalmic is used to treat itching of the eyes caused by allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances in the air).
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Canada | Ecuador | Egypt | India | Indonesia | Japan | Korea | Mexico | Philippines | Taiwan | United States | Uruguay
Approved Indications: Conjunctivitis | Conjunctivitis, Allergic
Known Adverse Events: Headache | Nasopharyngitis | Pharyngitis
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|